BioSpace News Archive

Caladrius Biosciences, Inc., announced that it has finalized an agreement to sell $10.9 million in New Jersey net operating losses to a qualifying and approved buyer pursuant to the New Jersey Economic Development Authority ’s Technology Business Tax Certificate Transfer Program.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, announced that CEO, John M. Climaco , will be issuing a shareholder webinar on April 22 nd , 2020 at 4:30pm ET to discuss the Company’s novel DNA-binding agent, WP1244, and to

The medical device company is also offering anyone free remote hearing checks and consultations, a limited-time discount, special financing and waived return fees

New wireless wearable pairs advanced TENS technology with Sweep Waveform Therapy to alleviate chronic, acute and arthritic knee pain, stiffness and discomfort

Myosana Therapeutics, Inc. , a new biotech company developing novel platform technology for non-viral gene delivery, raised up to $1M in seed financing from CureDuchenne Ventures . Myosana will use this initial funding to advance development of its innovative non-viral gene therapy to deliver full length dystrophin for Duchenne muscular dystrophy (DMD). Myosana Therapeutics was founded in 2018

SpeciCare Offers Patients Cancer Treatment Breakthrough For Newly Diagnosed and Re-Diagnosed Cancer Patients

New credit facilities provide up to $20 million in near-term liquidity In combination with cost-reduction initiatives, provide runway to complete value-enhancing development activities to seek approval of 180-day product

On 29 April, at 08:00 CET, Swedish Orphan Biovitrum AB will publish its report for the first quarter 2020.

Bimini Health Tech announced it received FDA 510 clearance for its novel Dermapose Refresh® Syringe-Based, Fat Transfer Technology.

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today announced that the Company will host a conference call and webcast on April 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2020 financial results.